Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study

BJ. Hanseeuw, V. Malotaux, L. Dricot, L. Quenon, Y. Sznajer, J. Cerman, JL. Woodard, C. Buckley, G. Farrar, A. Ivanoiu, R. Lhommel

. 2021 ; 48 (1) : 302-310. [pub] 20200629

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019523

Grantová podpora
SPD28094292 Fonds De La Recherche Scientifique - FNRS

PURPOSE: To evaluate cerebral amyloid-β(Aβ) pathology in older adults with cognitive complaints, visual assessment of PET images is approved as the routine method for image interpretation. In research studies however, Aβ-PET semi-quantitative measures are associated with greater risk of progression to dementia; but until recently, these measures lacked standardization. Therefore, the Centiloid scale, providing standardized Aβ-PET semi-quantitation, was recently validated. We aimed to determine the predictive values of visual assessments and Centiloids in non-demented patients, using long-term progression to dementia as our standard of truth. METHODS: One hundred sixty non-demented participants (age, 54-86) were enrolled in a monocentric [18F] flutemetamol Aβ-PET study. Flutemetamol images were interpreted visually following the manufacturers recommendations. SUVr values were converted to the Centiloid scale using the GAAIN guidelines. Ninety-eight persons were followed until dementia diagnosis or were clinically stable for a median of 6 years (min = 4.0; max = 8.0). Twenty-five patients with short follow-up (median = 2.0 years; min = 0.8; max = 3.9) and 37 patients with no follow-up were excluded. We computed ROC curves predicting subsequent dementia using baseline PET data and calculated negative (NPV) and positive (PPV) predictive values. RESULTS: In the 98 participants with long follow-up, Centiloid = 26 provided the highest overall predictive value = 87% (NPV = 85%, PPV = 88%). Visual assessment corresponded to Centiloid = 40, which predicted dementia with an overall predictive value = 86% (NPV = 81%, PPV = 92%). Inclusion of the 25 patients who only had a 2-year follow-up decreased the PPV = 67% (NPV = 88%), reflecting the many positive cases that did not progress to dementia after short follow-ups. CONCLUSION: A Centiloid threshold = 26 optimally predicts progression to dementia 6 years after PET. Visual assessment provides similar predictive value, with higher specificity and lower sensitivity. TRIAL REGISTRATION: Eudra-CT number: 2011-001756-12.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019523
003      
CZ-PrNML
005      
20210830101116.0
007      
ta
008      
210728s2021 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00259-020-04942-4 $2 doi
035    __
$a (PubMed)32601802
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Hanseeuw, Bernard J $u Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium. bernard.hanseeuw@uclouvain.be $u Neurology Department, Saint-Luc University Hospital, Av. Hippocrate, 10, 1200, Brussels, Belgium. bernard.hanseeuw@uclouvain.be $u Gordon Center for Medical Imaging, Radiology Department, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. bernard.hanseeuw@uclouvain.be
245    10
$a Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study / $c BJ. Hanseeuw, V. Malotaux, L. Dricot, L. Quenon, Y. Sznajer, J. Cerman, JL. Woodard, C. Buckley, G. Farrar, A. Ivanoiu, R. Lhommel
520    9_
$a PURPOSE: To evaluate cerebral amyloid-β(Aβ) pathology in older adults with cognitive complaints, visual assessment of PET images is approved as the routine method for image interpretation. In research studies however, Aβ-PET semi-quantitative measures are associated with greater risk of progression to dementia; but until recently, these measures lacked standardization. Therefore, the Centiloid scale, providing standardized Aβ-PET semi-quantitation, was recently validated. We aimed to determine the predictive values of visual assessments and Centiloids in non-demented patients, using long-term progression to dementia as our standard of truth. METHODS: One hundred sixty non-demented participants (age, 54-86) were enrolled in a monocentric [18F] flutemetamol Aβ-PET study. Flutemetamol images were interpreted visually following the manufacturers recommendations. SUVr values were converted to the Centiloid scale using the GAAIN guidelines. Ninety-eight persons were followed until dementia diagnosis or were clinically stable for a median of 6 years (min = 4.0; max = 8.0). Twenty-five patients with short follow-up (median = 2.0 years; min = 0.8; max = 3.9) and 37 patients with no follow-up were excluded. We computed ROC curves predicting subsequent dementia using baseline PET data and calculated negative (NPV) and positive (PPV) predictive values. RESULTS: In the 98 participants with long follow-up, Centiloid = 26 provided the highest overall predictive value = 87% (NPV = 85%, PPV = 88%). Visual assessment corresponded to Centiloid = 40, which predicted dementia with an overall predictive value = 86% (NPV = 81%, PPV = 92%). Inclusion of the 25 patients who only had a 2-year follow-up decreased the PPV = 67% (NPV = 88%), reflecting the many positive cases that did not progress to dementia after short follow-ups. CONCLUSION: A Centiloid threshold = 26 optimally predicts progression to dementia 6 years after PET. Visual assessment provides similar predictive value, with higher specificity and lower sensitivity. TRIAL REGISTRATION: Eudra-CT number: 2011-001756-12.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a Alzheimerova nemoc $7 D000544
650    _2
$a amyloidní beta-protein $x metabolismus $7 D016229
650    _2
$a aniliny $7 D000814
650    _2
$a benzothiazoly $7 D052160
650    _2
$a mozek $x metabolismus $7 D001921
650    12
$a kognitivní dysfunkce $x diagnostické zobrazování $7 D060825
650    12
$a demence $x diagnostické zobrazování $7 D003704
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pozitronová emisní tomografie $7 D049268
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Malotaux, Vincent $u Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
700    1_
$a Dricot, Laurence $u Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
700    1_
$a Quenon, Lisa $u Neurology Department, Saint-Luc University Hospital, Av. Hippocrate, 10, 1200, Brussels, Belgium
700    1_
$a Sznajer, Yves $u Genetics Department, Saint-Luc University Hospital, Brussels, Belgium
700    1_
$a Cerman, Jiri $u Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
700    1_
$a Woodard, John L $u Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium $u Department of Psychology, Wayne State University, Detroit, MI, USA
700    1_
$a Buckley, Christopher $u GE Healthcare, Amersham, UK
700    1_
$a Farrar, Gill $u GE Healthcare, Amersham, UK
700    1_
$a Ivanoiu, Adrian $u Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium $u Neurology Department, Saint-Luc University Hospital, Av. Hippocrate, 10, 1200, Brussels, Belgium
700    1_
$a Lhommel, Renaud $u Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium $u Nuclear Medicine Department, Saint-Luc University Hospital, Brussels, Belgium $u Institute of Experimental and Clinical Research, Université Catholique de Louvain, Brussels, Belgium
773    0_
$w MED00007222 $t European journal of nuclear medicine and molecular imaging $x 1619-7089 $g Roč. 48, č. 1 (2021), s. 302-310
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32601802 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101116 $b ABA008
999    __
$a ok $b bmc $g 1690365 $s 1139969
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 48 $c 1 $d 302-310 $e 20200629 $i 1619-7089 $m European journal of nuclear medicine and molecular imaging $n Eur J Nucl Med Mol Imaging $x MED00007222
GRA    __
$a SPD28094292 $p Fonds De La Recherche Scientifique - FNRS
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace